English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Public health is very important in big cities, and data analysis on public health studies is always a demanding issue that determines the study effectiveness. E-value was proposed as a standard sensitivity analysis tool to assess unmeasured confounders in observational studies, but its value is doubted. To evaluate the usefulness of E-value, in this paper, we collected 368 observational studies on drug effectiveness evaluation published from 1998 to September 2019 (out of 3426 searched studies) and evaluated the features of E-value. We selected the effects of primary outcomes or the largest effects in terms of hazard ratio, risk ratio, or odds ratio. Effects were transformed into estimated effect sizes following a standard E-value computation. In all 368 studies, the disease with the highest percentage was infections and infestations, at 21.7% (80/368). Our results showed that the median relative effect size was 1.89 (Q1-Q3: 1.41–2.95), and the corresponding median E-value was 3.19 with 95% confidence interval lower bound 1.77. Smaller studies yielded larger E-values for the effect size estimate and the relationship was considerably attenuated when considering the E-value for the lower bound of 95% confidence interval on the effect size. Notably, E-values have a monotonic, almost linear relationship with effect estimates. We found that E-value may cause misimpressions on the unmeasured confounder, and the same E-value does not reflect the varying nature of the unmeasured confounders in different studies, and there lacks a guidance on how E-value can be deemed as small or large, all of which limits the capability of E-value as a standard sensitivity analysis tool in real applications.

Assess the Application of the E-Value in the Unmeasured Confounder Evaluation of Observational Pharmaceutical Studies